BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18229466)

  • 1. Systemic sclerosis (scleroderma).
    Roufosse FE; de Bellefon LM
    Acta Clin Belg; 2007; 62(5):323-9. PubMed ID: 18229466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenic autoantibodies in systemic sclerosis.
    Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
    Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.
    Sakkas LI; Chikanza IC; Platsoucas CD
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):679-85. PubMed ID: 17133253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.
    Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV
    Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course.
    Becker MO; Riemekasten G
    Expert Rev Clin Immunol; 2016; 12(2):115-35. PubMed ID: 26558747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scleroderma.
    Gilliam AC
    Curr Dir Autoimmun; 2008; 10():258-79. PubMed ID: 18460891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
    Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.
    Harris ML; Rosen A
    Curr Opin Rheumatol; 2003 Nov; 15(6):778-84. PubMed ID: 14569210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis refractory disease: from the skin to the heart.
    Almeida I; Faria R; Vita P; Vasconcelos C
    Autoimmun Rev; 2011 Sep; 10(11):693-701. PubMed ID: 21575745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis.
    Hua-Huy T; Dinh-Xuan AT
    Pathol Biol (Paris); 2015 Apr; 63(2):61-8. PubMed ID: 25818311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells.
    Ishikawa H; Takeda K; Okamoto A; Matsuo S; Isobe K
    J Invest Dermatol; 2009 Jul; 129(7):1688-95. PubMed ID: 19158840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis.
    Badea I; Taylor M; Rosenberg A; Foldvari M
    Rheumatology (Oxford); 2009 Mar; 48(3):213-21. PubMed ID: 19022832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathophysiology of systemic sclerosis].
    Allanore Y
    Med Sci (Paris); 2016 Feb; 32(2):183-91. PubMed ID: 26936176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
    Hasegawa M
    J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
    Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
    Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis.
    Manetti M; Neumann E; Müller A; Schmeiser T; Saar P; Milia AF; Endlicher E; Roeb E; Messerini L; Matucci-Cerinic M; Ibba-Manneschi L; Müller-Ladner U
    Arthritis Rheum; 2008 Sep; 58(9):2866-73. PubMed ID: 18759276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis.
    Sato S; Hayakawa I; Hasegawa M; Fujimoto M; Takehara K
    J Invest Dermatol; 2003 Apr; 120(4):542-7. PubMed ID: 12648215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.